j j agrees 25bn guidant deal pharmaceutical giant johnson johnson agreed buy medical technology firm guidant 25.4bn â£13bn guidant key producer equipment combats heart problems implant defibrillators pacemakers analysts said deal aimed offsetting johnson johnson reliance slowing drug business pointed mergers likely drug healthcare industries fragmented pressure cut costs number johnson johnson products facing patent expirations company battling fierce competition generic products demand defibrillators heart small electric shock irregular heartbeat rhythm detected expected increase analysts said johnson johnson widely expected firm pay 76 guidant share 6 wednesday closing price analysts antitrust regulators force firms shed overlapping stent operations stents tubes artery open unblocked 